Skip to content

SELLAS Life Sciences Group, Inc.

SLS

CIK 0001390478 · Pharmaceutical Preparations · Nasdaq

  • GALENA BIOPHARMA, INC. (until 2017-12-15)
  • Galena Biopharma, Inc. (until 2017-12-15)
  • RXI PHARMACEUTICALS CORP (until 2011-09-21)
← back to feed
Revenue (TTM)
$0
−100.0% YoY Q1 May 2026
Net Income (TTM)
−$27.61M
+13.0% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.25
+50.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$40.89M
Q1 May 2026
Cash
$107.1M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
186.03M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings